Rafferty Asset Management LLC Purchases 22,593 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Rafferty Asset Management LLC boosted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 24.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 116,186 shares of the company’s stock after acquiring an additional 22,593 shares during the period. Rafferty Asset Management LLC’s holdings in Nurix Therapeutics were worth $2,189,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. US Bancorp DE boosted its holdings in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares in the last quarter. Aquatic Capital Management LLC bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $87,000. Summit Investment Advisors Inc. boosted its holdings in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after acquiring an additional 877 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $164,000. Finally, Nomura Holdings Inc. bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $198,000.

Wall Street Analyst Weigh In

NRIX has been the topic of a number of recent research reports. Morgan Stanley raised their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 3rd. Leerink Partners initiated coverage on Nurix Therapeutics in a report on Monday, March 17th. They issued a “market perform” rating and a $16.00 target price on the stock. Stephens restated an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. JPMorgan Chase & Co. dropped their target price on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Finally, Royal Bank of Canada raised their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.44.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,838 shares of company stock valued at $221,500 over the last ninety days. 7.40% of the stock is currently owned by insiders.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $10.14 on Wednesday. The business has a fifty day simple moving average of $10.91 and a two-hundred day simple moving average of $16.65. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The company has a market capitalization of $773.03 million, a P/E ratio of -3.51 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The business had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period last year, the business posted ($0.76) earnings per share. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.